Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| INT048 | Registry Identifier | INT048 596-MON-CRC-MUL |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Colorectal cancer is a major cause of cancer death in Chile. Many people with rectal cancer that has grown into nearby tissues receive chemotherapy and radiation before surgery. These treatments can cause tiredness and loss of muscle, which may make it harder for patients to complete treatment.
This study will look at whether a supervised strength-training exercise program is practical and safe during treatment before surgery. Participants will do a personalized strength-training program two times per week. The program will start when cancer treatment begins and will continue until surgery (about 24 weeks).
The study will measure how practical the program is by looking at how many people join the study, stay in the study, and attend the exercise sessions, and whether the study team can collect all planned information. The study will also track any problems or side effects related to exercise.
The study will also explore whether the exercise program may help maintain muscle, improve strength and physical function, improve quality of life, reduce fatigue, and affect how the tumor responds to treatment. These results will be compared with information from similar patients previously treated at the same hospital.
Eligible patients with locally advanced rectal adenocarcinoma treated at FALP and scheduled for RAPIDO total neoadjuvant therapy will be invited during routine visits.
Participants receive usual oncologic care plus a supervised, individualized resistance training program performed in the FALP Kinesiology Service gym. Each session lasts 60 minutes, twice weekly, from the start of neoadjuvant therapy to surgery (24 weeks).
Training loads are prescribed from baseline strength testing and progressed every 2 weeks; an intermediate clinical-functional assessment around week 8 supports safe adjustment. Assessments occur at baseline and within 48 hours before surgery. Data will be stored in REDCap.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Supervised Progressive Resistance Training | Experimental | Participants receive supervised, individualized progressive resistance training twice weekly (60 minutes/session) from start of neoadjuvant therapy until surgery (24 weeks). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Strength training program | Other | Individualized supervised progressive resistance training twice weekly (60 minutes/session) from start of neoadjuvant therapy to surgery (24 weeks), with loads prescribed from baseline strength testing and progressed every 2 weeks; safety monitored and adapted based on clinical status. |
| Measure | Description | Time Frame |
|---|---|---|
| Recruitment rate (enrolled among eligible patients) (%) | Primary Outcome Measure 1 - Recruitment Recruitment will be calculated as: (number of eligible patients who enroll ÷ number of eligible patients approached) × 100. The feasibility threshold is ≥60% of eligible patients agreeing to participate. | During the recruitment period |
| Retention rate (participants completing the intervention) (%) | Description: Retention will be calculated as: (number of enrolled participants who complete the intervention ÷ number enrolled) × 100. The feasibility threshold is ≥80% completing the intervention. | From enrollment through end of intervention (~24 weeks) |
| Mean adherence to planned supervised resistance-training sessions (%) | Adherence (individual-level) will be calculated as: (number of supervised sessions completed ÷ number of planned sessions) × 100. Study-level adherence will be reported as the mean of individual adherence percentages across all enrolled participants. Planned dose: 2 supervised sessions/week from start of neoadjuvant therapy until surgery (~24 weeks; total 48 sessions). The feasibility threshold is mean adherence ≥80% | From enrollment through end of intervention (~24 weeks) |
| Participants completing ≥80% of planned supervised sessions (%) | A participant will be considered adherent if they complete ≥80% of planned supervised sessions (≥39 of 48 sessions). The proportion of participants meeting this threshold will be calculated. The feasibility threshold is ≥75% of participants completing ≥80% of planned sessions. | From enrollment through end of intervention (~24 weeks) |
| Data completeness (completed scheduled assessments among planned assessments) (%) | Data completeness will be calculated as: (number of completed scheduled assessments ÷ number of planned assessments) × 100. The feasibility threshold is ≥85% of scheduled assessments completed. |
| Measure | Description | Time Frame |
|---|---|---|
| Participants with ≥1 exercise-related adverse event (CTCAE v6.0) (%) | Safety will be assessed as the proportion of participants experiencing ≥1 exercise-related adverse event during the intervention period. Exercise-related adverse events will be classified and graded using CTCAE v6.0. | From enrollment through end of intervention (24 weeks) |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline in cross-sectional skeletal muscle area at L3 measured by CT (cm²) | Description: Cross-sectional muscle area (CSA) at lumbar level L3 will be quantified using routine CT (thorax-abdomen-pelvis) at baseline and pre-surgery. Change from baseline will be analyzed. | Baseline and within 48 hours prior to rectal surgery (~24 weeks) |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Nicole M Caire, Medical Oncologist | Contact | +56974998222 | nicole.caire@falp.org |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Fundación Arturo López Pérez | Santiago | Santiago Metropolitan | 7500921 | Chile |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 32972439 | Background | Singh B, Hayes SC, Spence RR, Steele ML, Millet GY, Gergele L. Exercise and colorectal cancer: a systematic review and meta-analysis of exercise safety, feasibility and effectiveness. Int J Behav Nutr Phys Act. 2020 Sep 24;17(1):122. doi: 10.1186/s12966-020-01021-7. | |
| 34941028 | Background | Latrille M, Buchs NC, Ris F, Koessler T. Physical activity programmes for patients undergoing neo-adjuvant chemoradiotherapy for rectal cancer: A systematic review and meta-analysis. Medicine (Baltimore). 2021 Dec 23;100(51):e27754. doi: 10.1097/MD.0000000000027754. |
Not provided
Not provided
Recruitment rate, Mean Adherence and Safety profile
From March 2026 to March 2031
Research team using an institucional RedCap platform
Not provided
Single arm pilot study to mesure feasibility and safety of the intervention : a excercise program during the neoadjuvant treatment in patients with locally advaced rectal cancer
Not provided
Not provided
Not provided
Not provided
|
| From enrollment through end of intervention (~24 weeks) |
| Change from baseline in handgrip strength measured by dynamometer (kg) |
Handgrip strength will be measured using a handgrip dynamometer at baseline and post-prehabilitation. Change from baseline will be analyzed. |
| Baseline and within 48 hours prior to rectal surgery (~24 weeks) |
| Change from baseline in Short Physical Performance Battery (SPPB) score (points) | Physical performance will be measured using the Short Physical Performance Battery (SPPB). Change from baseline will be analyzed. | Baseline and within 48 hours prior to rectal surgery (~24 weeks) |
| Change from baseline in quality of life assessed by EORTC QLQ-C30 score (0-100) | Quality of life will be measured using the EORTC QLQ-C30 questionnaire. Scores range from 0 to 100. Change from baseline will be analyzed.Unit of Measure: Score (0-100) | Baseline and within 48 hours prior to rectal surgery (~24 weeks) |
| Change from baseline in cancer-related fatigue assessed by Brief Fatigue Inventory (BFI) score (0-10) | Fatigue will be measured using the Brief Fatigue Inventory (BFI). Scores range from 0 to 10. Change from baseline will be analyzed. | Baseline and within 48 hours prior to rectal surgery (~24 weeks) |
| Participant satisfaction with the exercise program assessed by CSQ-8 total score (8-32) | Satisfaction will be assessed using the Client Satisfaction Questionnaire (CSQ-8) at the end of the intervention.Unit of Measure: Score (8-32) | End of intervention (prior to surgery; ~24 weeks) |
| 34158253 | Background | Morielli AR, Usmani N, Boule NG, Severin D, Tankel K, Joseph K, Nijjar T, Fairchild A, Courneya KS. Feasibility, Safety, and Preliminary Efficacy of Exercise During and After Neoadjuvant Rectal Cancer Treatment: A Phase II Randomized Controlled Trial. Clin Colorectal Cancer. 2021 Sep;20(3):216-226. doi: 10.1016/j.clcc.2021.05.004. Epub 2021 May 26. |
| 29329555 | Background | Morielli AR, Usmani N, Boule NG, Severin D, Tankel K, Nijjar T, Joseph K, Fairchild A, Courneya KS. Exercise during and after neoadjuvant rectal cancer treatment (the EXERT trial): study protocol for a randomized controlled trial. Trials. 2018 Jan 12;19(1):35. doi: 10.1186/s13063-017-2398-1. |
| 30880749 | Background | Alejo LB, Pagola-Aldazabal I, Fiuza-Luces C, Huerga D, de Torres MV, Verdugo AS, Ortega Solano MJ, Felipe JL, Lucia A, Ruiz-Casado A. Exercise prehabilitation program for patients under neoadjuvant treatment for rectal cancer: A pilot study. J Cancer Res Ther. 2019 Jan-Mar;15(1):20-25. doi: 10.4103/jcrt.JCRT_30_17. |
| 34154675 | Background | Loughney L, West MA, Moyses H, Bates A, Kemp GJ, Hawkins L, Varkonyi-Sepp J, Burke S, Barben CP, Calverley PM, Cox T, Palmer DH, Mythen MG, Grocott MPW, Jack S; Fit4Surgery group. The effects of neoadjuvant chemoradiotherapy and an in-hospital exercise training programme on physical fitness and quality of life in locally advanced rectal cancer patients: a randomised controlled trial (The EMPOWER Trial). Perioper Med (Lond). 2021 Jun 22;10(1):23. doi: 10.1186/s13741-021-00190-8. |
| 30657249 | Background | Moug SJ, Mutrie N, Barry SJE, Mackay G, Steele RJC, Boachie C, Buchan C, Anderson AS. Prehabilitation is feasible in patients with rectal cancer undergoing neoadjuvant chemoradiotherapy and may minimize physical deterioration: results from the REx trial. Colorectal Dis. 2019 May;21(5):548-562. doi: 10.1111/codi.14560. Epub 2019 Feb 16. |
| 29936624 | Background | Cave J, Paschalis A, Huang CY, West M, Copson E, Jack S, Grocott MPW. A systematic review of the safety and efficacy of aerobic exercise during cytotoxic chemotherapy treatment. Support Care Cancer. 2018 Oct;26(10):3337-3351. doi: 10.1007/s00520-018-4295-x. Epub 2018 Jun 24. |
| 32065236 | Background | Campbell KL, Zadravec K, Bland KA, Chesley E, Wolf F, Janelsins MC. The Effect of Exercise on Cancer-Related Cognitive Impairment and Applications for Physical Therapy: Systematic Review of Randomized Controlled Trials. Phys Ther. 2020 Mar 10;100(3):523-542. doi: 10.1093/ptj/pzz090. |
| 40380237 | Background | Chen X, Zhang J, Gao F, Liu N, Du H, Li J, Li Z, Chen R. Exercise therapy: an effective approach to mitigate the risk of cancer metastasis. World J Surg Oncol. 2025 May 16;23(1):192. doi: 10.1186/s12957-025-03846-7. |
| 30878132 | Background | Bland KA, Zadravec K, Landry T, Weller S, Meyers L, Campbell KL. Impact of exercise on chemotherapy completion rate: A systematic review of the evidence and recommendations for future exercise oncology research. Crit Rev Oncol Hematol. 2019 Apr;136:79-85. doi: 10.1016/j.critrevonc.2019.02.005. Epub 2019 Feb 16. |
| 33220396 | Background | Zaorsky NG, Allenby T, Lin J, Rosenberg J, Simone NL, Schmitz KH. Exercise Therapy and Radiation Therapy for Cancer: A Systematic Review. Int J Radiat Oncol Biol Phys. 2021 Jul 15;110(4):973-983. doi: 10.1016/j.ijrobp.2020.11.024. Epub 2020 Nov 19. |
| 34215623 | Background | Yang L, Morielli AR, Heer E, Kirkham AA, Cheung WY, Usmani N, Friedenreich CM, Courneya KS. Effects of Exercise on Cancer Treatment Efficacy: A Systematic Review of Preclinical and Clinical Studies. Cancer Res. 2021 Oct 1;81(19):4889-4895. doi: 10.1158/0008-5472.CAN-21-1258. Epub 2021 Jul 2. |
| 30573180 | Background | Ashcraft KA, Warner AB, Jones LW, Dewhirst MW. Exercise as Adjunct Therapy in Cancer. Semin Radiat Oncol. 2019 Jan;29(1):16-24. doi: 10.1016/j.semradonc.2018.10.001. |
| 32738520 | Background | Wang Q, Zhou W. Roles and molecular mechanisms of physical exercise in cancer prevention and treatment. J Sport Health Sci. 2021 Mar;10(2):201-210. doi: 10.1016/j.jshs.2020.07.008. Epub 2020 Jul 30. |
| 39346906 | Background | Feng Y, Feng X, Wan R, Luo Z, Qu L, Wang Q. Impact of exercise on cancer: mechanistic perspectives and new insights. Front Immunol. 2024 Sep 13;15:1474770. doi: 10.3389/fimmu.2024.1474770. eCollection 2024. |
| 32648302 | Background | Schwappacher R, Schink K, Sologub S, Dieterich W, Reljic D, Friedrich O, Herrmann HJ, Neurath MF, Zopf Y. Physical activity and advanced cancer: evidence of exercise-sensitive genes regulating prostate cancer cell proliferation and apoptosis. J Physiol. 2020 Sep;598(18):3871-3889. doi: 10.1113/JP279150. Epub 2020 Jul 28. |
| 40699773 | Background | Sun Y, Ma Y, Shi L, Liu T, Dong Y, Jin Q. The Impact and Molecular Mechanisms of Exercise in Cancer Therapy. Curr Issues Mol Biol. 2025 May 20;47(5):374. doi: 10.3390/cimb47050374. |
| 35803475 | Background | Zhu C, Ma H, He A, Li Y, He C, Xia Y. Exercise in cancer prevention and anticancer therapy: Efficacy, molecular mechanisms and clinical information. Cancer Lett. 2022 Sep 28;544:215814. doi: 10.1016/j.canlet.2022.215814. Epub 2022 Jul 5. |
| 39518934 | Background | Natarajan A, Pradhan R, Dieterich W, Schwappacher R, Reljic D, Herrmann HJ, Neurath MF, Hack CC, Beckmann MW, Zopf Y. The Influence of Physical Training on Breast Cancer: The Role of Exercise-Induced Myokines in Regulating Breast Cancer Cell Growth and Survival. Int J Mol Sci. 2024 Oct 23;25(21):11379. doi: 10.3390/ijms252111379. |
| 38687441 | Background | He A, Pu Y, Jia C, Wu M, He H, Xia Y. The Influence of Exercise on Cancer Risk, the Tumor Microenvironment and the Treatment of Cancer. Sports Med. 2024 Jun;54(6):1371-1397. doi: 10.1007/s40279-024-02031-2. Epub 2024 Apr 30. |
| 40450658 | Background | Courneya KS, Vardy JL, O'Callaghan CJ, Gill S, Friedenreich CM, Wong RKS, Dhillon HM, Coyle V, Chua NS, Jonker DJ, Beale PJ, Haider K, Tang PA, Bonaventura T, Wong R, Lim HJ, Burge ME, Hubay S, Sanatani M, Campbell KL, Arthuso FZ, Turner J, Meyer RM, Brundage M, O'Brien P, Tu D, Booth CM; CHALLENGE Investigators. Structured Exercise after Adjuvant Chemotherapy for Colon Cancer. N Engl J Med. 2025 Jul 3;393(1):13-25. doi: 10.1056/NEJMoa2502760. Epub 2025 Jun 1. |